Lisocabtagene maraleucel achieved a 95.5% response rate in patients with relapsed/refracto ...

The chimeric antigen receptor (CAR) T cell therapy anitocabtagene autoleucel (anito-cel) continued to show strong results in ...

Research presented December 8 at the American Society of Hematology Conference in Florida, has shown that a new kind of CAR T ...

Discover the nuances of CAR T-cell therapy eligibility and its advantages over traditional chemotherapy for long-term patient ...

The global CAR T-Cell Therapy for Multiple Myeloma market is experiencing transformative growth, driven by advances in BCMA-targeted therapies like FDA-approved Abecma and Carvykti. These treatments ...

Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive CAR T cell therapy for multiple myeloma share a common immune root cause, ...

Aleta Biotherapeutics, a clinical stage immuno-oncology company developing CAR T-cell engager biologics that enable CAR T-cell cancer therapies to work more effectively, and Cancer Research UK’s ...

March Bio is continuing enrollment in the Phase 2 trial, with the Independent Data Monitoring Committee's approval to advance to Simon Stage 2 of the Phase 2 trial. The Company anticipates presenting ...

Chimeric antigen receptor (CAR) T-cell therapy can cure certain types of blood cancer, but cost and a general lack of ...

Key factors driving this growth include the rising prevalence of cancer, continuous advancements in CAR T-cell technologies, a ...

Outpatient CAR T-cell therapy shows promising efficacy and manageable safety in treating relapsed multiple myeloma, with high ...

Measuring the lymphocytes - white blood cells that fight infection - in a patient's blood can be used to predict outcomes in ...